Is MUGA scan necessary in patients with low-risk breast cancer before doxorubicin-based adjuvant therapy?

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 24, Issue 4, 2001, Pages 425-428

  Sabel, Michael S ^a   Levine, Ellis G ^a   Hurd, Thelma ^a   Schwartz, Gary N ^a   Zielinski, Robert ^a   Hohn, David ^a   Edge, Stephen B ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Adjuvant chemotherapy; Breast cancer; Doxorubicin; Multiple gated acquisition (MUGA); Radionuclide angiography

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; PERTECHNETIC ACID TC 99M; STANNOUS PYROPHOSPHATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DRUG INDUCED DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MULTIPLE GATED ACQUISITION SCAN; RISK FACTOR; SCINTIANGIOGRAPHY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DOXORUBICIN; FEMALE; GATED BLOOD-POOL IMAGING; HEART DISEASES; HUMANS; MIDDLE AGED; RISK FACTORS;

EID: 0034908478     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200108000-00027     Document Type: Article

References (23)

1. A clinicopathologic analysis of Adriamycin cardiotoxicity
2. Adriamycin cardiotoxicity; a survey of 1273 patients
3. Early and delayed clinical cardiotoxicity of doxorubicin
4. Risk factors for doxorubicin-induced congestive heart failure
5. Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity
6. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer (BC)
7. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results
8. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15
9. Adjuvant cyclophosphamide, methotrexate, and flourouracil in node-positive breast cancer. The results of 20 years of follow-up
10. Anthracyclines in cancer chemotherapy
11. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography
12. Adverse effects of treatment
13. Doxorubicin-induced cardiomyopathy
14. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy: Seven-year experience using serial radionuclide angiocardiography
15. Radionuclide ejection fraction in doxorubicin cardiotoxicity
16. Postoperative radiotherapy and late mortality: Evidence from the Cancer Research Campaign trial for early breast cancer
17. Postoperative radiotherapy in breast cancer-long term results from the Oslo study
18. Cardiac doses in post-operative breast irradiation
19. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients
20. Observations on cardiac toxicity in a treatment program containing Adriamycin and radiation therapy for stage III breast cancer: An Eastern Cooperative Oncology Group study
21. The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomized trial
22. Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: The MD Anderson experience
23. Efficacy and cost of cardiac monitoring in patients receiving doxorubicin